| Project/Area Number |
26861288
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | Nara Medical University |
|---|
Principal Investigator |
Lou Yi 奈良県立医科大学, 医学部, 研究員 (30633797)
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | 尿路上皮癌 / DNAメチル化 / 酸化ストレス / 膀胱癌 / 脱メチル化剤 / エピジェネティクス |
|---|
| Outline of Final Research Achievements |
In this study, I elucidated anti-tumor effects of the combination, which were 5-aza-CdR and metformin against urothelial cancer. AGEs accumulate in the cells which are exposed long term oxidant stress. I presented a hypothesis that the AGEs bind the DNA histone tails and close chromatin structures might results inhibit tumor suppressor genes such as p16 through epigenetic regulation. DNMT inhibitor, 5-aza-CdR showed anti-tumor effect for urothelial cancer in both in vivo and in vitro clearly, however the combination of 5-aza-CdR and metformin, which are inhibitor of AGEs formation did not show synergic effect. On the other hand, metformin progressed the re-expression of p16 through epigenetic regulation, that are open the chromatin.
|
